UNSPSC 51332402: Prifuroline

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OP2V3XRV2Y. European Medicines Agency schedules Prifuroline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10040MIG. Prifuroline generally arises in the molecular formula C14H16N2O.

UNSPSC 51332402 Prifuroline is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmaceutical prescriptions, and generic multi-source pharmaceuticals and OTC products — none of which align with prifuroline, a pharmaceutical ingredient with limited presence in state and local contracting. The code shows a mismatch between its nominal scope and actual procurement practice, suggesting either misclassification at the issuing office or dormancy of the prifuroline category itself in the state and local market.

Issuing bodies posting under this code span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The three recent opportunities originate from Seminole County, Florida (health services), the Texas Health and Human Services Commission (pharmacy benefit program), and the Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across the upper Midwest and Pacific Northwest. Geographic activity centers on Florida, Texas, and Minnesota. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capacity; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson.